Johnson & Johnson ($JNJ) - Big Pharma's Q3 2010 Earnings Report

FiercePharma says: J&J's third quarter was down 0.7 percent compared to the third quarter of 2009; however, sales were slightly up compared to the same timeframe, at $1.23 per share. Though U.S. sales declined 2.5 percent, the Asia-Pacific Africa region grew 4.1 percent, the strongest growth of the quarter. The company's consumer segment is still lagging--and mired with manufacturing issues--down 10.2 percent compared to 2009's third quarter; U.S. sales in this department were down 24.5 percent, and OTC product sales were down 19.4 percent--with a 40 percent loss in the U.S. and a slight gain (3.5 percent) overseas.

Highlights

  • Sales of $15.0 Billion Decreased 0.7% Versus 2009 Third-Quarter
  • EPS of $1.23 increased 2.5% Versus 2009 Third-Quarter

See J&J's current stock quote from CNN Money

J&J's website: http://www.jnj.com
J&J's full earnings release: J&J release

Johnson & Johnson ($JNJ) - Big Pharma's Q3 2010 Earnings Report
Read more on

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.